File Download
 
 
Supplementary

Conference Paper: Serologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearance
  • Basic View
  • Metadata View
  • XML View
TitleSerologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearance
 
AuthorsSeto, WK
Wong, DKH
Fung, J
Yuen, JCH
Hung, IFN
Lai, CL
Yuen, RMF
 
KeywordsMedical sciences
Gastroenterology
 
Issue Date2012
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
CitationThe 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012), Barcelona, Spain, 18-22 April 2012. In Journal of Hepatology, 2012, v. 56 suppl. 2 , p. S214-S215, abstract no. 541 [How to Cite?]
 
AbstractBACKGROUND: Hepatitis B surface antigen (HBsAg) seroclearance after nucleoside analogue (NA) therapy is an uncommon event. The serologic and virologic kinetics after HBsAg seroclearance and cessation of therapy have not been previously described. METHODS: Between December 1999 and June 2011, 42 (73.9% male) patients developed HBsAg seroclearance after NA therapy. Serum HBV DNA and HBsAg levels were determined at baseline, time of HBsAg loss and after cessation of therapy. They were measured by Cobas Taqman assay (lower limit of detection 20 IU/mL) and Roche Elecsys HBsAg II assay (lower limit of detection 0.05 IU/mL) respectively. RESULTS: HBsAg seroclearance occurred in a median duration of 48.8 (range: 4.8 to 189.0) months after therapy commencement. Twenty-nine (69.0%), 10 (23.8%), 2 (4.8%) and 1 (2.4%) patients were on lamivudine, entecavir, lamivudine plus adefovir and telbivudine respectively. At the time of writing, 22 patients (52.4%) developed anti-HBs. Seven patients (16.7%, 6 on lamivudine, 1 on entecavir) stopped therapy after a median treatment duration of 39.9 (range 12.8 to 112.4) months, before HBsAg seroclearance which occurred after at a median time of 36.4 (range 17.2 to 94.9) months. Of the 35 patients who continued taking NA till HBsAg seroclearance, 17 (48.6%) stopped therapy 17.9 (range 1.4 to 87.6) months after HBsAg seroclearance. Among patients with therapy ceased for more than 6 months (n = 14, median time 21.9 months, range 6.4 to 53.3 months), 13 (92.6%) maintained an undetectable level of serum HBV DNA and HBsAg. One patient (7.1%) developed HBsAg seroreversion and hepatitic flare 29 months after cessation of lamivudine. She achieved HBsAg seroclearance and viral suppression to undetectable levels again at 4 and 7 months respectively after retreatment of entecavir. There were no cases of HBsAg seroreversion among the 18 patients (51.4%) maintaining therapy 15.9 (range 3.7 to 58.8) months after HBsAg seroclearance. CONCLUSION: Majority of CHB patients who stopped treatment after CHB seroclearance maintained virologic and serologic stability.
 
DescriptionThis journal suupl. contain Abstracts of the 2012 International Liver Congress™ and the 47th EASL Annual Meeting
Poster no. 541
 
ISSN0168-8278
2013 Impact Factor: 10.401
 
DC FieldValue
dc.contributor.authorSeto, WK
 
dc.contributor.authorWong, DKH
 
dc.contributor.authorFung, J
 
dc.contributor.authorYuen, JCH
 
dc.contributor.authorHung, IFN
 
dc.contributor.authorLai, CL
 
dc.contributor.authorYuen, RMF
 
dc.date.accessioned2012-09-20T08:18:24Z
 
dc.date.available2012-09-20T08:18:24Z
 
dc.date.issued2012
 
dc.description.abstractBACKGROUND: Hepatitis B surface antigen (HBsAg) seroclearance after nucleoside analogue (NA) therapy is an uncommon event. The serologic and virologic kinetics after HBsAg seroclearance and cessation of therapy have not been previously described. METHODS: Between December 1999 and June 2011, 42 (73.9% male) patients developed HBsAg seroclearance after NA therapy. Serum HBV DNA and HBsAg levels were determined at baseline, time of HBsAg loss and after cessation of therapy. They were measured by Cobas Taqman assay (lower limit of detection 20 IU/mL) and Roche Elecsys HBsAg II assay (lower limit of detection 0.05 IU/mL) respectively. RESULTS: HBsAg seroclearance occurred in a median duration of 48.8 (range: 4.8 to 189.0) months after therapy commencement. Twenty-nine (69.0%), 10 (23.8%), 2 (4.8%) and 1 (2.4%) patients were on lamivudine, entecavir, lamivudine plus adefovir and telbivudine respectively. At the time of writing, 22 patients (52.4%) developed anti-HBs. Seven patients (16.7%, 6 on lamivudine, 1 on entecavir) stopped therapy after a median treatment duration of 39.9 (range 12.8 to 112.4) months, before HBsAg seroclearance which occurred after at a median time of 36.4 (range 17.2 to 94.9) months. Of the 35 patients who continued taking NA till HBsAg seroclearance, 17 (48.6%) stopped therapy 17.9 (range 1.4 to 87.6) months after HBsAg seroclearance. Among patients with therapy ceased for more than 6 months (n = 14, median time 21.9 months, range 6.4 to 53.3 months), 13 (92.6%) maintained an undetectable level of serum HBV DNA and HBsAg. One patient (7.1%) developed HBsAg seroreversion and hepatitic flare 29 months after cessation of lamivudine. She achieved HBsAg seroclearance and viral suppression to undetectable levels again at 4 and 7 months respectively after retreatment of entecavir. There were no cases of HBsAg seroreversion among the 18 patients (51.4%) maintaining therapy 15.9 (range 3.7 to 58.8) months after HBsAg seroclearance. CONCLUSION: Majority of CHB patients who stopped treatment after CHB seroclearance maintained virologic and serologic stability.
 
dc.descriptionThis journal suupl. contain Abstracts of the 2012 International Liver Congress™ and the 47th EASL Annual Meeting
 
dc.descriptionPoster no. 541
 
dc.identifier.citationThe 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012), Barcelona, Spain, 18-22 April 2012. In Journal of Hepatology, 2012, v. 56 suppl. 2 , p. S214-S215, abstract no. 541 [How to Cite?]
 
dc.identifier.epageS215
 
dc.identifier.hkuros211098
 
dc.identifier.issn0168-8278
2013 Impact Factor: 10.401
 
dc.identifier.issuesuppl. 2
 
dc.identifier.spageS214
 
dc.identifier.urihttp://hdl.handle.net/10722/165462
 
dc.identifier.volume56
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofJournal of Hepatology
 
dc.subjectMedical sciences
 
dc.subjectGastroenterology
 
dc.titleSerologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearance
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Seto, WK</contributor.author>
<contributor.author>Wong, DKH</contributor.author>
<contributor.author>Fung, J</contributor.author>
<contributor.author>Yuen, JCH</contributor.author>
<contributor.author>Hung, IFN</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Yuen, RMF</contributor.author>
<date.accessioned>2012-09-20T08:18:24Z</date.accessioned>
<date.available>2012-09-20T08:18:24Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012), Barcelona, Spain, 18-22 April 2012. In Journal of Hepatology, 2012, v. 56 suppl. 2 , p. S214-S215, abstract no. 541</identifier.citation>
<identifier.issn>0168-8278</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/165462</identifier.uri>
<description>This journal suupl. contain Abstracts of the 2012 International Liver Congress&#8482; and the 47th EASL Annual Meeting</description>
<description>Poster no. 541</description>
<description.abstract>BACKGROUND: Hepatitis B surface antigen (HBsAg) seroclearance after nucleoside analogue (NA) therapy is an uncommon event. The serologic and virologic kinetics after HBsAg seroclearance and cessation of therapy have not been previously described. METHODS: Between December 1999 and June 2011, 42 (73.9% male) patients developed HBsAg seroclearance after NA therapy. Serum HBV DNA and HBsAg levels were determined at baseline, time of HBsAg loss and after cessation of therapy. They were measured by Cobas Taqman assay (lower limit of detection 20 IU/mL) and Roche Elecsys HBsAg II assay (lower limit of detection 0.05 IU/mL) respectively. RESULTS: HBsAg seroclearance occurred in a median duration of 48.8 (range: 4.8 to 189.0) months after therapy commencement. Twenty-nine (69.0%), 10 (23.8%), 2 (4.8%) and 1 (2.4%) patients were on lamivudine, entecavir, lamivudine plus adefovir and telbivudine respectively. At the time of writing, 22 patients (52.4%) developed anti-HBs. Seven patients (16.7%, 6 on lamivudine, 1 on entecavir) stopped therapy after a median treatment duration of 39.9 (range 12.8 to 112.4) months, before HBsAg seroclearance which occurred after at a median time of 36.4 (range 17.2 to 94.9) months. Of the 35 patients who continued taking NA till HBsAg seroclearance, 17 (48.6%) stopped therapy 17.9 (range 1.4 to 87.6) months after HBsAg seroclearance. Among patients with therapy ceased for more than 6 months (n = 14, median time 21.9 months, range 6.4 to 53.3 months), 13 (92.6%) maintained an undetectable level of serum HBV DNA and HBsAg. One patient (7.1%) developed HBsAg seroreversion and hepatitic flare 29 months after cessation of lamivudine. She achieved HBsAg seroclearance and viral suppression to undetectable levels again at 4 and 7 months respectively after retreatment of entecavir. There were no cases of HBsAg seroreversion among the 18 patients (51.4%) maintaining therapy 15.9 (range 3.7 to 58.8) months after HBsAg seroclearance. CONCLUSION: Majority of CHB patients who stopped treatment after CHB seroclearance maintained virologic and serologic stability.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jhep</publisher>
<relation.ispartof>Journal of Hepatology</relation.ispartof>
<subject>Medical sciences</subject>
<subject>Gastroenterology</subject>
<title>Serologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearance</title>
<type>Conference_Paper</type>
<identifier.hkuros>211098</identifier.hkuros>
<identifier.volume>56</identifier.volume>
<identifier.issue>suppl. 2</identifier.issue>
<identifier.spage>S214</identifier.spage>
<identifier.epage>S215</identifier.epage>
<publisher.place>Netherlands</publisher.place>
</item>